Orphazyme ApS is a Copenhagen, Denmark–based company focused on protein misfolding. The company has been raising capital through a Series B financing. It completed a second and final close of €14 million on March 10, 2017. That second close brought the Series B round's total to €34 million after a €20 million first close announced in January 2015. New investors in the second close included LSP and the ALS Investment Fund, alongside existing backers Kurma Partners, Idinvest Partners, Novo A/S (Hellerup, Denmark), Sunstone Capital and Aescap Venture. Orphazyme ApS is a Copenhagen, Denmark-based developer of novel therapeutics targeting rare and genetic diseases. Led by CEO Anders Hinsby, the company's lead program is in preclinical development as a treatment for lysosomal storage diseases. Lysosomal storage diseases comprise more than 45 genetic disorders, most of which are currently untreatable and often fatal. Financially, Orphazyme completed a €20m Series B financing and had previously raised more than €17m in seed and Series A rounds. Past financings include a €14m Series A (09/09/2011) and a DKK 22m seed round (27/03/2011). Orphazyme ApS is a Copenhagen, Denmark-based biopharmaceutical company developing medicines for a family of genetic lysosomal storage diseases. Its lead program, Orph-001, is a recombinant version of human HSP70 being developed to treat these disorders, which primarily affect children. The company intends to use the Series A proceeds to progress Orph-001 into clinical development. Orphazyme is led by CEO Anders Hinsby and is based on discoveries from the laboratory of Professor Marja Jäättela and Dr. Thomas Kirkegaard Jensen at the Danish Cancer Society. It has established collaborations with academic institutions in Europe and the USA. Financially, the company completed a €14m Series A to fund near-term clinical advancement of its lead program. Orphazyme is a Copenhagen-based company developing therapies for a family of lysosomal storage diseases. Its technology is based on discoveries from Professors Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. The company is starting to prepare its lead project for clinical development and has established collaborations with top-tier academic institutions in Europe and the USA. Orphazyme was founded in 2009 and is led by CEO Anders Hinsby. Financially, the company completed a seed financing of DDK 22m to advance its programs.

Total raised

$61M

Funding rounds

4

Latest round

Series B

Latest activity

Mar 2017